Scagliola R, Rosa GM. Is Takotsubo cardiomyopathy still looking for its own nosological identity? World J Cardiol 2022; 14(10): 557-560 [PMID: 36339885 DOI: 10.4330/wjc.v14.i10.557]
Corresponding Author of This Article
Riccardo Scagliola, MD, Doctor, Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi n. 10, Genoa 16132, Italy. risca88@live.it
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. Oct 26, 2022; 14(10): 557-560 Published online Oct 26, 2022. doi: 10.4330/wjc.v14.i10.557
Is Takotsubo cardiomyopathy still looking for its own nosological identity?
Riccardo Scagliola, Gian Marco Rosa
Riccardo Scagliola, Gian Marco Rosa, Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino, Genoa 16132, Italy
Author contributions: Scagliola R and Rosa GM contributed to the conception and design of the manuscript; Scagliola R drafted the manuscript; all authors contributed equally to the critical revision, editing and approval of the final version of the manuscript.
Conflict-of-interest statement: All authors have no conflicts of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Riccardo Scagliola, MD, Doctor, Cardiovascular Disease Unit, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi n. 10, Genoa 16132, Italy. risca88@live.it
Received: May 7, 2022 Peer-review started: May 7, 2022 First decision: May 31, 2022 Revised: May 31, 2022 Accepted: October 5, 2022 Article in press: October 5, 2022 Published online: October 26, 2022
Abstract
Despite several efforts to provide a proper nosological framework for Takotsubo cardiomyopathy (TCM), this remains an unresolved matter in clinical practice. Several clinical, pathophysiologic and histologic findings support the conceivable hypothesis that TCM could be defined as a unique pathologic entity, rather than a distinct subset of myocardial infarction with non-obstructive coronary arteries. Further investigations are needed in order to define TCM with the most appropriate disease taxonomy.
Core Tip: Despite several efforts to provide a proper nosological framework for Takotsubo cardiomyopathy (TCM), this remains an unresolved matter in clinical practice. Several clinical, pathophysiologic and histologic findings support the conceivable hypothesis that TCM could be defined as a unique pathologic entity, rather than a distinct subset of myocardial infarction with non-obstructive coronary arteries. These issues need to be confirmed by further investigations, in order to define TCM with the most appropriate disease taxonomy.
